Joseph D. Buxbaum, PhD, a pioneering researcher in the field of autism, recently was elected to the National Academy of Medicine, considered one of the highest honors in medicine. New members are elected annually by current active members through a selective process that recognizes individuals who have made major contributions to advance medical sciences, health care, and public health.
A world-renowned molecular geneticist and neurobiologist, Dr. Buxbaum is Professor and Vice Chair for Research in the Department of Psychiatry, and Director of the Seaver Autism Center for Research and Treatment at Icahn School of Medicine at Mount Sinai. He is also Professor of Neuroscience, and Genetics and Genomic Sciences, and the G. Harold and Leila Y. Mathers Research Professor of Geriatrics and Adult Development.
Dr. Buxbaum was recognized for his significant contributions to uncovering the genetic and molecular basis of neuropsychiatric disorders, including Alzheimer’s disease, schizophrenia, and autism spectrum disorder.
His research focuses on using techniques of molecular genetics and neuroscience to identify and characterize genes that contribute to disease susceptibility. His laboratory has identified common and rare genetic variants that underlie autism and has developed model systems in which novel therapeutics can be tested. His work has led to clinical trials in rare genetic disorders associated with autism.
As the founder and co-leader of the Autism Sequencing Consortium, Dr. Buxbaum also heads an international group of scientists who share autism samples, data, and ideas to accelerate the understanding of the causes of and treatments for autism.
“Dr. Buxbaum’s election is a notable achievement and well-deserved recognition of his leadership and important contributions to uncovering the genetic and molecular basis of autism spectrum disorder,” says Dennis S. Charney, MD, the Anne and Joel Ehrenkranz Dean, Icahn School of Medicine at Mount Sinai and President for Academic Affairs, Mount Sinai Health System.